Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | SVP, Corporate Controller | September 13, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date September 13, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,615.41 |
Reported balance
After 2026-09-13 transaction · row 1
1 source rowRow 1 · 2026-09-13 · Tax withholding · Disposed 253 · Balance 14,615.41 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2026 Filed Sep 14, 2026 22:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 253 | $84.37 | $21,345.61 |
DisclosureSEC source: 0001225208-26-007811 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,615.41 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e). Read SEC document |
| August 31, 2026 Filed Aug 31, 2026 21:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 544 | $91.06 | $49,533.92 |
DisclosureSEC source: 0001225208-26-007408 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,868.41 Read SEC document |
| May 29, 2026 Filed May 29, 2026 20:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 567.5266 | $86.08 | $48,852.69 |
DisclosureSEC source: 0001225208-26-005647 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,334.0948 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 289 | $82.76 | $23,917.64 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · nonDerivative · entry 3 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,901.6214 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 6,745 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · derivative · entry 4 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,745 Underlying: Common Stock · 6,745 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · nonDerivative · entry 2 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,190.6214 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,170.6214 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| February 22, 2026 Filed Feb 23, 2026 22:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 176 | $79.78 | $14,041.28 |
DisclosureSEC source: 0001225208-26-002408 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,089.4805 Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 00:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-009137 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,183.074 F1 · shares: These restricted stock units were granted on November 13, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| September 13, 2025 Filed Sep 15, 2025 22:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 262 | $77.57 | $20,323.34 |
DisclosureSEC source: 0001225208-25-007992 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,926.9331 Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 5,670 | $0.00 Strike: $74.63 | $0.00 |
DisclosureSEC source: 0001225208-25-004946 · doc4.xml · derivative · entry 2 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,670 Underlying: Common Stock · 5,670 shares Expires 2032-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:34 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 3,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-004946 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,106.5266 F1 · shares: These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| February 22, 2025 Filed Feb 24, 2025 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 176 | $73.30 | $12,900.80 |
DisclosureSEC source: 0001225208-25-002308 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,684.1255 Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-008721 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,690.7834 F1 · shares: These restricted stock units were granted on September 13, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.